GlassScriptPhysician profile
Tracy L Pankey
NPI 1043525629
$9,387.71
in general payments reported to CMS, 2019-2025
18 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,943 · 2022: $1,101 · 2023: $2,600 · 2024: $1,837 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,315 · Education: $29.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,314.82 |
| Education | $29.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,544.52 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,334.49 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,199.87 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,171.78 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $671.07 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $560.30 | 2021-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $543.99 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $531.93 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $464.94 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $399.47 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.45 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $219.21 | 2021-2024 | Trintellix |
| Lundbeck LLC | $157.35 | 2022-2025 | Rexulti |
| Indivior INC. | $95.57 | 2021-2023 | Perseris, Sublocade |
| Almatica Pharma LLC | $81.96 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39.33 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $34.21 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $29.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Pankey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.